DOCSLIB.ORG

Pharmacological Characteristics of Insect Nicotinic Acetyicholine Receptor with Its Ion Channel and the Comparison of the Effect of Nicotinoids and Neonicotinoids

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pharmacological Characteristics of Insect Nicotinic Acetyicholine Receptor with Its Ion Channel and the Comparison of the Effect of Nicotinoids and Neonicotinoids J. Pesticide Sci. 20, 57-64 (1995) Original Article Pharmacological Characteristics of Insect Nicotinic Acetyicholine Receptor with Its Ion Channel and the Comparison of the Effect of Nicotinoids and Neonicotinoids Motohiro TOMIZAWA, Hiroko OTSUKA, Toru MIYAMOTO, Mohyee E. ELDEFRAWI* and Izuru YAMAMOTO Department of Agricultural Chemistry, Tokyo University of Agriculture, Setagaya-ku, Tokyo 156, Japan *Department of Pharmacology and Experimental Therapeutics, University of Maryland School of Medicine, Baltimore, MD 21201, U. S. A. (Received July S, 1994; Accepted September 26, 1994) Using radioreceptor assay with [3H]ce-bungarotoxin (a-BGT) and [3H]phencyclidine (PCP) as probes for the nicotinic acetylcholine receptor (nAChR) in membranes obtained from honeybee heads, the effects of various nAChR ligands, nicotinoids and neonicotinoids were studied. The data indicated differences in pharmacological characteristics between Torpedo electric organ and honeybee brain nAChRs. [3H]a-BGT binds to the acetylcholine (ACh) recognition site of the nAChRs of vertebrate skeletal muscle, Torpedo electric organ and honeybee brain. In vertebrates, [3H]PCP binds to an allosteric site on the receptors ion channel and its binding is stimulated by receptor activation with agonists. However, the tested vertebrate cholinergic agonists inhibited [3H]a-BGT binding, but did not activate [3H]PCP binding to the honeybee nAChR. Saturation isotherms of the binding of [3H]a-BGT with or without PCP indicated that PCP interacted with the ACh recognition site on the nAChR. Furthermore, nicotine inhibited not only [3H]a-BGT binding but also [3H]PCP binding. Detailed study of [3H]PCP binding indicated that [3H]PCP bound to the honeybee brain membranes both at high and low affinity sites. The former corresponded to the verte- brate allosteric site on the nAChR and the latter to the ACh recognition site. Nicotine, anabasine and nitenpyram bound to both sites, while imidacloprid, 6-Cl-PMNI and acet- amiprid bound selectively to the ACh recognition site. In houseflies, nicotine and imida- cloprid produced excitation followed by paralysis, while PCP was anesthetic, even though PCP was as insecticidal as nicotine. was also demonstrated by the voltage-depend- INTRODUCTION ent blockade of the ACh-induced current by Pharmacological characteristics of the nico- historionicotoxin, 4 PCP5 and the analog of tinic acetylcholine receptor (nAChR) has fire ant venom, cis-2-methyl-6-undecylpiperi- been studied in Torpedo electric organ by using dine. 6 However, unlike binding to the [3H]perhydrohistorionicotoxin (H12-HTX)1 and Torpedo nAChR, the binding of [3H]H12-HTX [3H]phencyclidine (PCP)23 as probes of the and [3H]PCP to the insect nAChRs, was not allosteric site located in the receptors ion activated by cholinergic agonists. 7 Also, the channel. The presence of the allosteric site in binding of [3H] or [125I]a-bungarotoxin (a- the ion channel of the nAChR of the cockroach BGT), which binds to the ACh recognition site (Periplaneta americana) central nervous system of insect nAChRs, 89 was almost unaffected by 58 日本 農 薬 学 会 誌 第20巻 第1号 平 成7年2長 H12-HTX or PCP. 57 studies.) Other tested ligands were pur- Recently developed novel insecticides, imi- chased from Sigma Chemical or Wako Pure dacloprid and related compounds, were shown Chemical. to interact with the insect nAChR. IO-12 The similarity between imidacloprid related com- 2. nAChR Preparation from the Honeybee pounds and nicotinoids was indicated by Heads 16) structure-activity relationships. The term Honeybee (Apis mellifera) heads collected by neonicotinoids was proposed to cover imi- sieving of liquid nitrogen frozen honeybees dacloprid related compounds. 14 The effects were homogenized three times in ten volumes of neonicotinoids on the binding of [H] PCP to of 50mM Na2HPO4-HC1 buffer, pH 7.4, con- the nAChR in Torpedo electric organ were taining 320mM sucrose and 1mM EDTA in compared with that of nicotinoids. It was Polytron (setting 7) for 30 sec each with a 60 shown that neonicotinoids were weaker nAChR sec rest. The homogenate was filtered through agonists than nicotinoids. In the present four layers of cheesecloth to remove the de- study, the authors also found that the binding bris. The filtrate was centrifuged at 1000xg properties of [H] PCP to the nAChR from the for 10min, and the supernatant was centri- honeybee head were quite different from those fuged at 40,000xg for 30min. The pellet was to the Torpedo nAChR. Therefore, the phar- suspended in 1 mM Na2HPO4-HC1 buffer, pH macological characteristics of insect nAChR 7.4 (1g head/ml), and the suspension was with its ion channel were studied in detail frozen by immersion in a dry ice-methanol using various nAChR ligands, nicotinoids and mixture, lyophilized and stored at -80C. neonicotinoids. The lyophilized membranes contained ca. 0.3 mg protein /mg membranes. MATERIALSAND METHODS 1. Materials 3. [H]PCP Binding [Piperidyl-3, 4-H(N)]phencyclidine ([H] - The nAChR preparation (ca. 0.3mg protein PCP; 52 Ci/mmol), and N-[propionyl-H]pro- assay) was incubated at 25C for 30min (for pionylated a-bungarotoxin ([H]a-BGT; 68 saturation isotherm experiment) or 40 sec (for Cifmmol) were purchased from New England other experiments) with 5nM of [H]PCP and Nuclear Research Products and Amersham, with or without tested ligand at appropriate respectively. concentrations, in a total volume of 250 al of PCP and N- [1-(2-thienyl)cyclohexyl]piperi- 20 mM Tris-HC1 buffer, pH 7.4 containing 0.1 dine (TCP) were synthesized by the method of mM diisopropylfluorophosphate (to inhibit Kalir et al. and were handled under the acetylcholinesterase) and 0.02% sodium azide. license issued by governor of Tokyo metro- The reaction was terminated by rapid filtra- polis. tion on the GF JB filter (Whatman) that had 1-(6-Chloro-3-pyridylmethyl)-2-nitroimino- been presoaked in 0.05% polyethyleneimine. imidazolidine (imidacloprid), 1-(6-chloro-3-py- The GF/B filter was rinsed three times with 2. 5 ridylmethyl)-2-nitromethylene-imidazolidine ml of 0.9% NaCI and transferred into a count- (6-C1-PMNI) and 2-(nitromethylene)-tetra- ing vial. The radioactivity was counted after hydro-l, 3-thiazine (NMTHT) were obtained overnight incubation in 4 ml of scintillation from Nihon Bayer Agrochem. 1-[N-(6-Chloro- cocktail (Ready Protein, Beckman). Specific 3-pyridylmethyl)-N-ethyl]amino-1-methyl- binding was defined as the difference in radio- amino-2-nitroethene (nitenpyram) was ob- activity on the filter in the absence and tained from Takeda Chemical. N1-[(6-Chloro- presence of 100/GMunlabeled PCP. 3-pyridyl) methyl]-N2-cyano-N1-methylacet- amidine (acetamiprid) was obtained from 4. [H]c-BGT Binding Nippon Soda. l-Methylthioethyl-2-nitrometh- The nAChR preparation (ca. 0.4-0.5mg ylene-imidazolidine (MTENI) was obtained protein/assay) was incubated at 25C for 60 from Mitsui Toatsu Chemicals. Trimethaphan min with 2nM of [H]a-BGT, with or without camsylate was available from our earlier the tested ligand. The total volume was 250 Journal of Pesticide Science 20 (1) February 1995 59 ul of 20mM Na2HPO4-HC1buffer, pH 7.4 con- taining 1mM EDTA and 0.1mM phenyl- methylsulfonyl fluoride. Filtration and count- ing were the same as used for [3H]PCP binding. Specific binding was defined as the difference in counts in the absence and the presence of 2uM unlabeled a-BGT. 5. Data Analysis Saturation isotherms were obtained by dis- placing 10nM of [3H]PCP or 2nM of [8H]a- BGT binding with unlabeled PCP or a-BGT, respectively (at various concentrations), and analyzed by iterative nonlinear least-squares B regression using the LIGAND program with McPhersons modification for an IBM personal computer (Biosoft, Cambridge, U. K.). IC5o values (the molar concentration necessary for inhibiting 50% of specific binding) were deter- mined by iterative nonlinear least-squares regression using the SIGMAPLOT program (Jandel Scientific CA, U. S.A.). Inhibition constant (K;) was calculated by the equation: K1=IC5o/l+[L]/KD, where [L] is a concentration of the added Fig. 1 Effect of l-nicotine and PCP on the radiolabelled ligand and KD is a dissociation binding of [3H]a-BGT (A) and [3H]PCP (B) to the constant from a saturation isotherm. membranes from the honeybee heads. Symbols are means of three experiments. 6. Insecticidal Activity and Symptomatology One microliter of the compound in acetone TCP which are known as the noncompetitive was topically applied on the notum of 3-4 blockers of the nAChRs from the Torpedo days old female housefly (Musca domestica). electric organ and vertebrate muscle-8 gave Administration of imidacloprid was carried out the same effect. These ligands also strongly by intrathoracic injection of 0.22sl in 25% inhibited [8H]cc-BGTbinding to the honeybee dimethyl sulfoxide solution in water. Symp- nAChR (Fig. 1, Table 1). The same results toms of intoxication were observed and mor- were shown on the binding of both radio- talities were recorded after 24hr at 27+2C ligands using fresh membranes from the and 60% relative humidity. housefly heads. The IC50 values of PCP and 1-nicotine for [8H]a-BGT binding were 7.05+ RESULTSAND DISCUSSION 1.13, uM (n=3) and 3.30+0.62M (n=2), re- 1. Effect of Various Ligands on the Binding of spectively, and the IC5o values of PCP and [3H]PCP and [8H]a-BGT to the Honeybee 1-nicotine for [3H]PCP binding were 0.0562+ nAChR 0.00971uM (n=3) and 38.5+2.11uM (n=2), Eldefrawi et al. 7 indicated that [3H]Hi2- respectively. HTX or [8H]PCP binding to the housefly In case of the honeybee head nAChR, ligands nAChR was not increased by the presence of that had a high affinity to the [8H]a-BGT any vertebrate cholinergic ligand. The same binding site were PCP (1), TCP (2), lobeline was observed with honeybee nAChR.
Load more

Recommended publications
  • Chemicals in the Fourth Report and Updated Tables Pdf Icon[PDF
    Chemicals in the Fourth National Report on Human Exposure to Environmental Chemicals: Updated Tables, March 2021 CDC’s Fourth National Report on Human Exposure to Environmental Chemicals: Updated Tables, March 2021 provides exposure data on the following chemicals or classes of chemicals. The Updated Tables contain cumulative data from national samples collected beginning in 1999–2000 and as recently as 2015-2016. Not all chemicals were measured in each national sample. The data tables are available at https://www.cdc.gov/exposurereport. An asterisk (*) indicates the chemical has been added since publication of the Fourth National Report on Human Exposure to Environmental Chemicals in 2009. Adducts of Hemoglobin Acrylamide Formaldehyde* Glycidamide Tobacco Alkaloids and Metabolites Anabasine* Anatabine* Cotinine Cotinine-n-oxide* Hydroxycotinine* Trans-3’-hydroxycotinine* 1-(3-Pyridyl)-1-butanol-4-carboxylic acid* Nicotine* Nicotine-N’-oxide* Nornicotine* Tobacco-Specific Nitrosamines (TSNAs) N’-Nitrosoanabasine (NAB)* N’-Nitrosoanatabine (NAT)* N’-Nitrosonornicotine (NNN)* Total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol) (NNAL)* Volatile N-nitrosamines (VNAs) N-Nitrosodiethylamine (NDEA)* N-Nitrosoethylmethylamine (NMEA)* N-Nitrosomorpholine (NMOR)* N-Nitrosopiperidine (NPIP)* N-Nitrosopyrrolidine (NPYR)* Disinfection By-Products Bromodichloromethane Dibromochloromethane Tribromomethane (Bromoform) Trichloromethane (Chloroform) Personal Care and Consumer Product Chemicals and Metabolites Benzophenone-3 Bisphenol A Bisphenol F* Bisphenol
    [Show full text]
  • Molecular Mechanisms Associated with Nicotine Pharmacology and Dependence
    Molecular Mechanisms Associated with Nicotine Pharmacology and Dependence Christie D. Fowler, Jill R. Turner, and M. Imad Damaj Contents 1 Introduction 2 Basic Neurocircuitry of Nicotine Addiction 3 Role of Nicotinic Receptors in Nicotine Dependence and Brain Function 4 Modulatory Factors That Influence nAChR Expression and Signaling 5 Genomics and Genetics of Nicotine Dependence 5.1 Overview 5.2 Human and Animal Genetic Studies 5.3 Transcriptionally Adaptive Changes 6 Other Constituents in Nicotine and Tobacco Products Mediating Dependence 7 Therapeutic Approaches for Tobacco and Nicotine Dependence 7.1 Nicotine Replacement Therapies 7.2 Varenicline and Bupropion 7.3 Novel Approaches 8 Conclusion References Abstract Tobacco dependence is a leading cause of preventable disease and death world- wide. Nicotine, the main psychoactive component in tobacco cigarettes, has also C. D. Fowler Department of Neurobiology and Behavior, University of California Irvine, Irvine, CA, USA J. R. Turner Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY, USA M. Imad Damaj (*) Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA, USA Translational Research Initiative for Pain and Neuropathy at VCU, Richmond, VA, USA e-mail: [email protected] # Springer Nature Switzerland AG 2019 Handbook of Experimental Pharmacology, https://doi.org/10.1007/164_2019_252 C. D. Fowler et al. been garnering increased popularity in its vaporized form, as derived from e-cigarette devices. Thus, an understanding of the molecular mechanisms under- lying nicotine pharmacology and dependence is required to ascertain novel approaches to treat drug dependence. In this chapter, we review the field’s current understanding of nicotine’s actions in the brain, the neurocircuitry underlying drug dependence, factors that modulate the function of nicotinic acetylcholine receptors, and the role of specific genes in mitigating the vulnerability to develop nicotine dependence.
    [Show full text]
  • Addictions and the Brain
    9/18/2012 Addictions and the Brain TAAP Conference September 14, 2012 Acknowledgements • La Hacienda Treatment Center • American Society of Addiction Medicine • National Institute of Drug Abuse © 2012 La Hacienda Treatment Center. All rights reserved. 1 9/18/2012 Definition • A primary, progressive biochemical, psychosocial, genetically transmitted chronic disease of relapse who’s hallmarks are denial, loss of control and unmanageability. DSM IV Criteria for dependency: At least 3 of the 7 below 1. Withdrawal 2. Tolerance 3. The substance is taken in larger amounts or over a longer period than was intended. 4. There is a persistent desire or unsuccessful efforts to cut down or control substance use. 5. A great deal of time is spent in activities necessary to obtain the substance, use the substance, or recover from its effects. 6. Important social, occupational, or recreational activities are given up or reduced because of the substance use. 7. The substance use is continued despite knowledge of having a persistent or recurrent physical or psychological problem that is likely to have been caused or exacerbated by the substance. © 2012 La Hacienda Treatment Center. All rights reserved. 2 9/18/2012 Dispute between behavior and disease Present understanding of the Hypothalamus location of the disease hypothesis. © 2012 La Hacienda Treatment Center. All rights reserved. 3 9/18/2012 © 2012 La Hacienda Treatment Center. All rights reserved. 4 9/18/2012 © 2012 La Hacienda Treatment Center. All rights reserved. 5 9/18/2012 Dispute regarding behavior versus disease © 2012 La Hacienda Treatment Center. All rights reserved. 6 9/18/2012 © 2012 La Hacienda Treatment Center.
    [Show full text]
  • Upregulation of Peroxisome Proliferator-Activated Receptor-Α And
    Upregulation of peroxisome proliferator-activated receptor-α and the lipid metabolism pathway promotes carcinogenesis of ampullary cancer Chih-Yang Wang, Ying-Jui Chao, Yi-Ling Chen, Tzu-Wen Wang, Nam Nhut Phan, Hui-Ping Hsu, Yan-Shen Shan, Ming-Derg Lai 1 Supplementary Table 1. Demographics and clinical outcomes of five patients with ampullary cancer Time of Tumor Time to Age Differentia survival/ Sex Staging size Morphology Recurrence recurrence Condition (years) tion expired (cm) (months) (months) T2N0, 51 F 211 Polypoid Unknown No -- Survived 193 stage Ib T2N0, 2.41.5 58 F Mixed Good Yes 14 Expired 17 stage Ib 0.6 T3N0, 4.53.5 68 M Polypoid Good No -- Survived 162 stage IIA 1.2 T3N0, 66 M 110.8 Ulcerative Good Yes 64 Expired 227 stage IIA T3N0, 60 M 21.81 Mixed Moderate Yes 5.6 Expired 16.7 stage IIA 2 Supplementary Table 2. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis of an ampullary cancer microarray using the Database for Annotation, Visualization and Integrated Discovery (DAVID). This table contains only pathways with p values that ranged 0.0001~0.05. KEGG Pathway p value Genes Pentose and 1.50E-04 UGT1A6, CRYL1, UGT1A8, AKR1B1, UGT2B11, UGT2A3, glucuronate UGT2B10, UGT2B7, XYLB interconversions Drug metabolism 1.63E-04 CYP3A4, XDH, UGT1A6, CYP3A5, CES2, CYP3A7, UGT1A8, NAT2, UGT2B11, DPYD, UGT2A3, UGT2B10, UGT2B7 Maturity-onset 2.43E-04 HNF1A, HNF4A, SLC2A2, PKLR, NEUROD1, HNF4G, diabetes of the PDX1, NR5A2, NKX2-2 young Starch and sucrose 6.03E-04 GBA3, UGT1A6, G6PC, UGT1A8, ENPP3, MGAM, SI, metabolism
    [Show full text]
  • Sílvia Vilares Conde
    Sílvia Vilares Conde FUNCTIONAL SIGNIFICANCE OF ADENOSINE IN CAROTID BODY CHEMOSENSORY ACTIVITY IN CONTROL AND CHRONICALLY HYPOXIC ANIMALS Lisboa, 2007 a Dissertation presented to obtain the PhD degree in “Ciências da Vida – Especialidade Farmacologia” at the Faculdade de Ciências Médicas, Universidade Nova de Lisboa and Biotecnología: Aplicaciones Biomédicas at the Facultad de Medicina, Universidad de Valladolid Supervised by Profs. Constancio Gonzalez, Emília Monteiro and Ana Obeso. b Realizado com o apoio da Fundação para a Ciência e Tecnologia, SFRH/BD/14178/2003 financiada pelo POCI 2010 no âmbito da Formação avançada para a Ciência, Medida IV.3. c To my mum and dad d This work: Originated the following publications: - Conde S.V., Obeso A., Vicario I., Rigual R., Rocher A. and Gonzalez C. (2006), Caffeine inhibition of rat carotid body chemoreceptors is mediated by A2A and A2B adenosine receptors, J. Neurochem., 98, 616-628. (Chapter 3) - Conde S.V. and Monteiro E.C. (2006), Activation of nicotinic ACh receptors with α4 subunits induces adenosine release at the rat carotid body, Br. J. Pharmacol., 147, 783-789. (Chapter 2) - Conde S.V. and Monteiro E.C. (2004), Hypoxia induces adenosine release from the rat carotid body, J. Neurochem., 89 (5), 1148-1156. (Chapter 1) - Conde S.V. and Monteiro E.C. (2003), Adenosine-acetylcholine interactions at the rat carotid body, In: “Chemoreception: From cellular signalling to functional plasticity”, JM Pequinot et al. (Eds), Klumer Academic Press London, 305-311. (Chapter 2) Won the following awards: - 1st Prize “De Castro-Heymans–Neil Award” awarded by ISAC (International Society for Arterial Chemoreception) to the best work presented by a Young Researcher each triennial ISAC Meeting, 2002 - Pfizer Honor Young Researcher Prize awarded by the Portuguese Society of Medical Sciences, 2002 e Functional significance of adenosine in carotid body chemoreception PhD thesis, Silvia Vilares Conde INDEX Page List of Figures and Tables………………………………………………………..
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • Poisons and Narcotic Drugs (Amendment) Ordinance 1988
    AUSTRALIAN CAPITAL TERRITORY Poisons and Narcotic Drugs (Amendment) Ordinance 1988 No. 96 of 1988 I, THE GOVERNOR-GENERAL of the Commonwealth of Australia, acting with the advice of the Federal Executive Council, hereby make the following Ordinance under the Seat of Government (Administration) Act 1910. Dated 15 December 1988 N. M. STEPHEN Governor-General By His Excellency’s Command, CLYDE HOLDING Minister of State for the Arts and Territories An Ordinance to amend the Poisons and Narcotic Drugs Ordinance 1978 Short title 1. This Ordinance may be cited as the Poisons and Narcotic Drugs (Amendment) Ordinance 1988.1 Commencement 2. This Ordinance commences on such date as is fixed by the Minister by notice in the Gazette. Principal Ordinance 3. In this Ordinance, “Principal Ordinance” means the Poisons and Narcotic Drugs Ordinance 1978.2 (Ord. 79/88)—Cat. No. Authorised by the ACT Parliamentary Counsel—also accessible at www.legislation.act.gov.au 2 Poisons and Narcotic Drugs (Amendment) No. 96, 1988 Substances to which Division applies 4. Section 27B of the Principal Ordinance is amended by adding at the end the following paragraphs: “; (f) follicle stimulating hormone; (g) luteinising hormone; (h) thalidomide.”. Grant of authorisation 5. Section 27E of the Principal Ordinance is amended— (a) by omitting from paragraph (1) (a) “or cyclofenil” and substituting “, cyclofenil, follicle stimulating hormone or luteinising hormone”; (b) by omitting from paragraph (1) (b) “and”; and (c) by adding at the end of subsection (1) the following word and paragraph: “; and (d) in the case of an application that relates to thalidomide— the applicant is a specialist physician with no less than 5 years’ experience in the treatment of erythema nodosum leprosum.”.
    [Show full text]
  • Characterization of Mice with Altered Dopamine Transporter and Vesicular Monoamine Transporter 2 Levels
    Characterization of Mice with Altered Dopamine Transporter and Vesicular Monoamine Transporter 2 Levels by Shababa Tanzeel Masoud A thesis submitted in conformity with the requirements for the degree of Doctor of Philosophy Pharmacology and Toxicology University of Toronto © Copyright by Shababa Tanzeel Masoud 2017 Characterization of Mice with Altered Dopamine Transporter and Vesicular Monoamine Transporter 2 Levels Shababa Tanzeel Masoud Doctor of Philosophy Department of Pharmacology and Toxicology University of Toronto 2017 Abstract Dopamine is a key neurotransmitter that regulates motor coordination and dysfunction of the dopamine system gives rise to Parkinson’s disease. Nigrostriatal dopamine neurons are vulnerable to various genetic and environmental insults, suggesting that these cells are inherently at-risk. A cell-specific risk factor for these neurons is the neurotransmitter, dopamine itself. If intracellular dopamine is not appropriately sequestered into vesicles, it can accumulate in the cytosol. Cytosolic dopamine is highly reactive and can trigger oxidative stress, leading to cellular toxicity. Cytosolic dopamine levels are modulated by the plasma membrane dopamine transporter (DAT) that takes up dopamine from the extracellular space, and the vesicular monoamine transporter 2 (VMAT2) that stores dopamine into vesicles. In this thesis, we altered DAT and VMAT2 levels to investigate the detrimental consequences of potentially amplifying cytosolic dopamine in transgenic mice. Project 1 focused on selective over-expression of DAT in dopaminergic cells of transgenic mice (DAT-tg). DAT-tg mice displayed phenotypes of dopaminergic damage: increased dopamine-specific oxidative stress, L-DOPA-reversible fine motor deficits and enhanced sensitivity to toxicant insult, suggesting that increasing DAT- mediated dopamine uptake is detrimental for dopamine cells.
    [Show full text]
  • Pdf; Chi 2015 DPP Air in Cars.Pdf; Dodson 2014 DPP Dust CA.Pdf; Kasper-Sonnenberg 2014 Phth Metabolites.Pdf; EU Cosmetics Regs 2009.Pdf
    Bouge, Cathy (ECY) From: Nancy Uding <[email protected]> Sent: Friday, January 13, 2017 10:24 AM To: Steward, Kara (ECY) Cc: Erika Schreder Subject: Comments re. 2016 CSPA Rule Update - DPP Attachments: DPP 131-18-0 exposure.pdf; Chi 2015 DPP air in cars.pdf; Dodson 2014 DPP dust CA.pdf; Kasper-Sonnenberg 2014 phth metabolites.pdf; EU Cosmetics Regs 2009.pdf Please accept these comments from Toxic-Free Future concerning the exposure potential of DPP for consideration during the 2016 CSPA Rule update. Regards, Nancy Uding -- Nancy Uding Grants & Research Specialist Toxic-Free Future 206-632-1545 ext.123 http://toxicfreefuture.org 1 JES-00888; No of Pages 9 JOURNAL OF ENVIRONMENTAL SCIENCES XX (2016) XXX– XXX Available online at www.sciencedirect.com ScienceDirect www.elsevier.com/locate/jes Determination of 15 phthalate esters in air by gas-phase and particle-phase simultaneous sampling Chenchen Chi1, Meng Xia1, Chen Zhou1, Xueqing Wang1,2, Mili Weng1,3, Xueyou Shen1,4,⁎ 1. College of Environmental & Resource Sciences, Zhejiang University, Hangzhou 310058, China 2. Zhejiang National Radiation Environmental Technology Co., Ltd., Hangzhou 310011, China 3. School of Environmental and Resource Sciences, Zhejiang Agriculture and Forestry University, Hangzhou 310058, China 4. Zhejiang Provincial Key Laboratory of Organic Pollution Process and Control, Hangzhou 310058, China ARTICLE INFO ABSTRACT Article history: Based on previous research, the sampling and analysis methods for phthalate esters (PAEs) Received 24 December 2015 were improved by increasing the sampling flow of indoor air from 1 to 4 L/min, shortening the Revised 14 January 2016 sampling duration from 8 to 2 hr.
    [Show full text]
  • NINDS Custom Collection II
    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
    [Show full text]
  • Selective Knockdown of TASK3 Potassium Channel in Monoamine
    Manuscript Click here to download Manuscript Fullana et al - TASK3.docx 1 Research Article – Molecular Neurobiology 2 3 Selective Knockdown of TASK3 Potassium Channel in Monoamine 4 Neurons: A New Therapeutic Approach for Depression 5 M Neus Fullana1,2,3*, Albert Ferrés-Coy1,2,3*, Jorge E Ortega3,4, Esther Ruiz-Bronchal1,2,3, Verónica 6 Paz1,2,3, J Javier Meana3,4, Francesc Artigas1,2,3 and Analia Bortolozzi1,2,3 7 8 1Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain 9 2Department of Neurochemistry and Neuropharmacology, IIBB-CSIC (Consejo Superior de 10 Investigaciones Científicas), Barcelona, Spain. 11 3Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), ISCIII, Madrid, Spain. 12 4Department of Pharmacology, University of Basque Country UPV/EHU and BioCruces Health 13 Research Institute, Bizkaia, Spain 14 15 NF* and AF-C* contributed equally to this work. 16 For correspondence: Analia Bortolozzi, Department of Neurochemistry and Neuropharmacology 17 (IIBB-CSIC), Institut d’Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Rosello 161, 18 Barcelona 08036, Spain. Tel: +34 93638313 Fax: +34 933638301 E-mail: 19 [email protected] 20 21 22 23 Running title: Intranasal delivery of conjugated TASK3-siRNA 24 25 26 1 Abstract 2 Current pharmacological treatments for major depressive disorder (MDD) are severely compromised 3 by both slow action and limited efficacy. RNAi strategies have been used to evoke antidepressant-like 4 effects faster than classical drugs. Using small interfering RNA (siRNA), we herein show that TASK3 5 potassium channel knockdown in monoamine neurons induces antidepressant-like responses in mice.
    [Show full text]
  • Studies on New Pharmacological Treatments for Alcohol Dependence - and the Importance of Objective Markers of Alcohol Consumption
    Studies on new pharmacological treatments for alcohol dependence - and the importance of objective markers of alcohol consumption Andrea de Bejczy 2016 Addiction Biology Unit Section of Psychiatry and Neurochemistry Institute of Neuroscience and Physiology Sahlgrenska Academy at University of Gothenburg Sweden Cover illustration: by A. de Bejczy Inspired by Stan Lee’s “The Invincible Ironman. The empty shell”, Marvel Comics “…HIS VOICE IS HOARSE, HIS HAND TREMBLING AS HE REACHES FOR THE GLEAMING OBJECT THAT SEEMS BOTH WONDERFUL AND TERRIBLE TO HIM…” Studies on new pharmacological treatments for alcohol dependence ©Andrea de Bejczy [email protected] ISBN: 978-91-628-9788-8 (printed publication) ISBN: 978-91-628-9789-5 (e-publication) http://hdl.handle.net/2077/42349 Printed in Gothenburg, Sweden 2016 By INEKO ii La familia iii iv Studies on new pharmacological treatments for alcohol dependence - and the importance of objective markers of alcohol consumption Andrea de Bejczy Addiction Biology Unit Section of Psychiatry and Neurochemistry Institute of Neuroscience and Physiology Sahlgrenska Academy at University of Gothenburg ABSTRACT This thesis will guide you through three randomized controlled trials (RCT) on three pharmacotherapies for alcohol dependence; the antidepressant drug mirtazapine, the smoking cessation drug varenicline and the glycine-uptake inhibitor Org 25935. The mirtazapine study was an investigator initiated single- center harm-reduction study with alcohol consumption measured by self-report in a diary as main outcome. The results indicated that mirtazapine reduced alcohol consumption in males with heredity for alcohol use disorder (AUD). The Org 25935 study was an international multi-center study with abstinence as treatment goal, main time to relapse and alcohol consumption was measured by self-report collected by the Time Line Follow Back method (TLFB).
    [Show full text]